Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

679 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study.
Wolf AS, Bjørlykke KH, Ørbo HS, Bhandari S, Solum G, Kjønstad IF, Jyssum I, Nygaard UC, Kristoffersen AB, Christensen IE, Josefsson SE, Lund KP, Chopra A, Osen JR, Chaban V, Tveter AT, Sexton J, Kvien TK, Jahnsen J, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Kared H, Lund-Johansen F, Munthe LA, Syversen SW, Goll GL, Jørgensen KK, Mjaaland S. Wolf AS, et al. Among authors: kvien tk. EBioMedicine. 2024 Oct;108:105317. doi: 10.1016/j.ebiom.2024.105317. Epub 2024 Sep 10. EBioMedicine. 2024. PMID: 39260039 Free PMC article.
Generic Tofacitinib-A More Affordable JAK Inhibitor.
Goll GL, Kvien TK. Goll GL, et al. Among authors: kvien tk. Mayo Clin Proc. 2024 Jan;99(1):4-6. doi: 10.1016/j.mayocp.2023.11.014. Mayo Clin Proc. 2024. PMID: 38176834 No abstract available.
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.
Brun MK, Gehin JE, Bjørlykke KH, Warren DJ, Klaasen RA, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Jahnsen J, Bolstad N, Jørgensen KK, Haavardsholm EA, Goll GL, Syversen SW. Brun MK, et al. Among authors: kvien tk. Lancet Rheumatol. 2024 Apr;6(4):e226-e236. doi: 10.1016/S2665-9913(23)00341-7. Epub 2024 Feb 22. Lancet Rheumatol. 2024. PMID: 38402891 Clinical Trial.
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.
Brun MK, Bjørlykke KH, Viken MK, Stenvik GE, Klaasen RA, Gehin JE, Warren DJ, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Haavardsholm EA, Jahnsen J, Goll GL, Lie BA, Bolstad N, Jørgensen KK, Syversen SW. Brun MK, et al. Among authors: kvien tk. J Intern Med. 2023 May;293(5):648-655. doi: 10.1111/joim.13616. Epub 2023 Feb 26. J Intern Med. 2023. PMID: 36843323
Biosimilar tocilizumab-better access and lower cost?
Goll GL, Kvien TK. Goll GL, et al. Among authors: kvien tk. Lancet Rheumatol. 2024 Jan;6(1):e6-e8. doi: 10.1016/S2665-9913(23)00268-0. Lancet Rheumatol. 2024. PMID: 38258681 No abstract available.
Developing and externally validating multinomial prediction models for methotrexate treatment outcomes in patients with rheumatoid arthritis: results from an international collaboration.
Gehringer CK, Martin GP, Hyrich KL, Verstappen SMM, Sexton J, Kristianslund EK, Provan SA, Kvien TK, Sergeant JC. Gehringer CK, et al. Among authors: kvien tk. J Clin Epidemiol. 2024 Feb;166:111239. doi: 10.1016/j.jclinepi.2023.111239. Epub 2023 Dec 8. J Clin Epidemiol. 2024. PMID: 38072179 Free article.
679 results